PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock
- PMID: 7630120
- DOI: 10.1006/jsre.1995.1147
PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock
Abstract
Septic shock following gram-negative infection is a leading cause of mortality in critically ill patients, accounting for nearly 200,000 deaths a year. The exaggerated production of tumor necrosis factor-alpha (TNF alpha) is known to contribute to hemodynamic collapse and the hematological dyscrasia associated with gram-negative sepsis. Although previous studies have shown TNF alpha antibodies and TNF immunoadhesins to be effective in experimental gram-negative sepsis, we postulated that administration of a novel construct of two modified soluble p55 receptors linked to polyethylene glycol (PEG-BP-30) would also attenuate the hemodynamic and hematologic alterations to lethal Escherichia coli septic shock in non-human primates. Nine adult female and male baboons (Papio anubis), weighing 10-17 kg, were anesthetized and invasively monitored. The nine animals were randomized to receive either 0.2 mg/kg body wt PEG-BP-30 (n = 3), 5.0 mg/kg body wt PEG-BP-30 (n = 3), or placebo (n = 3). One hour after pretreatment, animals were infused with 5-10 x 10(10) CFU/kg of live E. coli iv and vital signs were recorded for the next 8 hr. Arterial blood was drawn for baseline parameters and throughout the study to obtain total and differential white blood cell and platelet counts and cytokine levels (TNF alpha, IL-1 beta, IL-6, IL-8). E. coli bacteremic baboons receiving only placebo demonstrated a significant fall in mean blood pressure and leukopenia. Two of the three animals expired. In contrast, five of the six baboons receiving the PEG-BP-30 survived and these animals exhibited markedly attenuated declines in blood pressure and leukocyte numbers.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis.Crit Care Med. 1995 Jun;23(6):1080-9. doi: 10.1097/00003246-199506000-00014. Crit Care Med. 1995. PMID: 7774220
-
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.J Clin Invest. 1992 May;89(5):1551-7. doi: 10.1172/JCI115748. J Clin Invest. 1992. PMID: 1533231 Free PMC article.
-
Does N-acetyl-L-cysteine influence cytokine response during early human septic shock?Chest. 1998 Jun;113(6):1616-24. doi: 10.1378/chest.113.6.1616. Chest. 1998. PMID: 9631802 Clinical Trial.
-
Biology of proinflammatory cytokines and their antagonists.Crit Care Med. 1994 Jul;22(7):S3-7. Crit Care Med. 1994. PMID: 8026189 Review.
-
Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants.Crit Care Med. 2001 Jul;29(7 Suppl):S78-89. doi: 10.1097/00003246-200107001-00026. Crit Care Med. 2001. PMID: 11445739 Review.
Cited by
-
Scientific and clinical challenges in sepsis.Curr Pharm Des. 2009;15(16):1918-35. doi: 10.2174/138161209788453248. Curr Pharm Des. 2009. PMID: 19519432 Free PMC article. Review.
-
Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice.Mol Med. 1997 Dec;3(12):864-75. Mol Med. 1997. PMID: 9440119 Free PMC article.
-
Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation.J Exp Med. 1997 Dec 1;186(11):1831-41. doi: 10.1084/jem.186.11.1831. J Exp Med. 1997. PMID: 9382882 Free PMC article.
-
Glucocorticoids and TNFalpha interact cooperatively to mediate sepsis-induced leucine resistance in skeletal muscle.Mol Med. 2006 Nov-Dec;12(11-12):291-9. doi: 10.2119/2006–00071.Lang. Mol Med. 2006. PMID: 17380194 Free PMC article.
-
PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I73-81. doi: 10.1136/ard.58.2008.i73. Ann Rheum Dis. 1999. PMID: 10577978 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical